This study investigates how well therapy guided by response and biology-based risk factors works for treating young patients with non-high risk neuroblastoma. Neuroblastoma is a type of cancer that forms in certain types of nerve tissue and is most commonly found in children. The study aims to tailor treatment based on how the disease responds and the biological risk factors involved.

Participants will undergo specific procedures to assess the effectiveness of the therapy. These procedures may include imaging tests and other assessments to monitor the disease and the body's response to the treatment. The goal is to determine if adjusting therapy based on these factors can improve outcomes for young patients.

• Who can participate: Children who are 12 months old at diagnosis with specific types of neuroblastoma can participate. They must have newly diagnosed non-amplified MYCN neuroblastoma or ganglioneuroblastoma. Patients with MYCN amplified tumors are not eligible.
• Study details: Participants will receive therapy based on their response and biological risk factors. This means the treatment may change depending on how the disease is reacting and certain biological markers. There is no placebo used in this study.